Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked higher than
79% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. OMED: No Debt )
OMED' s 10-Year Cash to Debt Range
Min: 326.31   Max: No Debt
Current: No Debt

Equity to Asset 0.33
OMED's Equity to Asset is ranked higher than
56% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OMED: 0.33 )
OMED' s 10-Year Equity to Asset Range
Min: -2.45   Max: 0.7
Current: 0.33

-2.45
0.7
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
97% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMED: No Debt )
OMED' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 1.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -74.77
OMED's Operating margin (%) is ranked higher than
74% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. OMED: -74.77 )
OMED' s 10-Year Operating margin (%) Range
Min: -161.06   Max: -48.52
Current: -74.77

-161.06
-48.52
Net-margin (%) -78.55
OMED's Net-margin (%) is ranked higher than
74% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. OMED: -78.55 )
OMED' s 10-Year Net-margin (%) Range
Min: -152.47   Max: -47.87
Current: -78.55

-152.47
-47.87
ROE (%) -38.78
OMED's ROE (%) is ranked higher than
72% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. OMED: -38.78 )
OMED' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -38.78

ROA (%) -14.73
OMED's ROA (%) is ranked higher than
78% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. OMED: -14.73 )
OMED' s 10-Year ROA (%) Range
Min: -28.05   Max: -12.61
Current: -14.73

-28.05
-12.61
ROC (Joel Greenblatt) (%) -769.51
OMED's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. OMED: -769.51 )
OMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -495.29   Max: -385.14
Current: -769.51

-495.29
-385.14
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OMED Guru Trades in Q4 2013

PRIMECAP Management 340,700 sh (+39.23%)
Steven Cohen Sold Out
» More
Q1 2014

OMED Guru Trades in Q1 2014

PRIMECAP Management 340,700 sh (unchged)
» More
Q2 2014

OMED Guru Trades in Q2 2014

Jim Simons 59,200 sh (New)
PRIMECAP Management 266,400 sh (-21.81%)
» More
Q3 2014

OMED Guru Trades in Q3 2014

PRIMECAP Management 218,400 sh (-18.02%)
Jim Simons 40,110 sh (-32.25%)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 Reduce -21.81%$21.21 - $32.59 $ 22.9-7%266400
PRIMECAP Management 2013-12-31 Add 39.23%$12.31 - $29.65 $ 22.926%340700
PRIMECAP Management 2013-09-30 New Buy$15.98 - $27.18 $ 22.923%244700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.59
OMED's P/B is ranked higher than
71% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. OMED: 7.59 )
OMED' s 10-Year P/B Range
Min: 3.52   Max: 9.74
Current: 7.59

3.52
9.74
P/S 13.43
OMED's P/S is ranked higher than
80% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. OMED: 13.43 )
OMED' s 10-Year P/S Range
Min: 1.03   Max: 15.29
Current: 13.43

1.03
15.29
PFCF 6.56
OMED's PFCF is ranked higher than
99% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: 6.56 )
OMED' s 10-Year PFCF Range
Min: 4.95   Max: 49.97
Current: 6.56

4.95
49.97
POCF 6.43
OMED's POCF is ranked higher than
99% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: 6.43 )
OMED' s 10-Year POCF Range
Min: 4.85   Max: 44.85
Current: 6.43

4.85
44.85
EV-to-EBIT -11.50
OMED's EV-to-EBIT is ranked higher than
83% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OMED: -11.50 )
OMED' s 10-Year EV-to-EBIT Range
Min: -31.4   Max: -6.5
Current: -11.5

-31.4
-6.5
Current Ratio 6.27
OMED's Current Ratio is ranked higher than
79% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. OMED: 6.27 )
OMED' s 10-Year Current Ratio Range
Min: 1.89   Max: 6.27
Current: 6.27

1.89
6.27
Quick Ratio 6.27
OMED's Quick Ratio is ranked higher than
80% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OMED: 6.27 )
OMED' s 10-Year Quick Ratio Range
Min: 1.89   Max: 6.27
Current: 6.27

1.89
6.27
Days Sales Outstanding 15.12
OMED's Days Sales Outstanding is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. OMED: 15.12 )
OMED' s 10-Year Days Sales Outstanding Range
Min: 0.22   Max: 59.49
Current: 15.12

0.22
59.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.94
OMED's Price/Net Cash is ranked higher than
83% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 55.00 vs. OMED: 9.94 )
OMED' s 10-Year Price/Net Cash Range
Min: 5.05   Max: 11.29
Current: 9.94

5.05
11.29
Price/Net Current Asset Value 9.69
OMED's Price/Net Current Asset Value is ranked higher than
83% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 31.07 vs. OMED: 9.69 )
OMED' s 10-Year Price/Net Current Asset Value Range
Min: 4.64   Max: 11.29
Current: 9.69

4.64
11.29
Price/Tangible Book 7.59
OMED's Price/Tangible Book is ranked higher than
76% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. OMED: 7.59 )
OMED' s 10-Year Price/Tangible Book Range
Min: 4.22   Max: 9.37
Current: 7.59

4.22
9.37
Price/Median PS Value 1.61
OMED's Price/Median PS Value is ranked higher than
77% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. OMED: 1.61 )
OMED' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 1.73
Current: 1.61

0.15
1.73
Earnings Yield (Greenblatt) -8.70
OMED's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. OMED: -8.70 )
OMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -8.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc was incorporated in July 2004 in Delaware. The Company is a clinical development-stage biotechnology company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells. The Company's operations are based in Redwood City, California. On July 17, 2013, the Company's registration statement on Form S-1 (File No. 333-181331) relating to the initial public offering of its common stock was declared effective by the SEC. The Company has five anti-CSC product candidates in clinical development. Additionally, other antibodies are in preclinical development with Investigational New Drug filings planned for as early as late 2014 or 2015. The first candidate, demcizumab, has completed a single-agent Phase Ia safety and dose escalation trial and is currently in Phase Ib combination therapy trials in patients with non-small cell lung cancer and pancreatic cancer and a Phase Ib/II trial combining demcizumab with paclitaxel in ovarian cancer. The second candidate, anti-Notch2/3 (OMP-59R5), is in a Phase Ib/II trial in pancreatic cancer in combination therapy with gemcitabine and Abraxane and a second Phase Ib/II trial in small cell lung cancer in combination therapy with etoposide and cisplatin chemotherapy. The third candidate, vantictumab (OMP-18R5), continues in a single-agent Phase Ia trial, and the Company has recently initiated three separate Phase Ib combination trials, one trial each in patients with breast cancer, pancreatic cancer, and non-small-cell lung cancer. The fourth candidate, Fzd8-Fc (OMP-54F28), is in a single-agent Phase Ia safety and dose escalation trial in solid tumor malignancies, and has begun three Phase Ib trials, one trial in each of pancreatic cancer, ovarian cancer, and hepatocellular carcinoma, of OMP-54F28 in combination with standard-of-care therapies. The fifth candidate, anti-Notch1 (OMP-52M51), is in two single-agent Phase Ia safety and dose escalation trials in hematologic and solid tumor malignancies.The Company purchases quantities of its product candidates from its contract manufacturers pursuant to purchase orders that it places from time to time. It competes in the segments of the pharmaceutical, biotechnology and other related markets that address solid tumor cancers and hematologic cancers. It also faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements on the clinical development, manufacture, marketing and distribution of its product candidates.
» More Articles for OMED

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare... Jan 28 2015
Nasdaq stocks posting largest percentage decreases Jan 27 2015
OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic... Jan 16 2015
OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic... Jan 16 2015
OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog Jan 16 2015
OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial in... Jan 15 2015
OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial in... Jan 15 2015
OncoMed to Present Clinical Data and Biomarker Analysis for Tarextumab at the 2015 Gastrointestinal... Jan 13 2015
OncoMed to Present Clinical Data and Biomarker Analysis for Tarextumab at the 2015 Gastrointestinal... Jan 13 2015
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 12 2015
OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance Jan 12 2015
OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance Jan 12 2015
OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
5 Bay Area life sciences companies looking to win big in 2015 Jan 05 2015
OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody Jan 05 2015
Alan Mendelson sees biotech's biggest risk — and it may surprise you Dec 30 2014
ASH: The Celgene show, this time through partners Dec 08 2014
OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in... Dec 01 2014
OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in... Dec 01 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK